查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胃食管反流藥物全球市場規模調查和預測，按藥物類型（抗酸劑、H2 受體阻滯劑、質子泵抑製劑 (PPI)、促動力藥），區域分析，2022-2029 年
市場調查報告書
商品編碼
1258052

胃食管反流藥物全球市場規模調查和預測，按藥物類型（抗酸劑、H2 受體阻滯劑、質子泵抑製劑 (PPI)、促動力藥），區域分析，2022-2029 年

Global Gastroesophageal Reflux Disease Therapeutics Market Size study & Forecast, by Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents), and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球胃食管反流藥物市場價值 51.8 億美元，在預測的 2022-2029 年預測期內以超過 1.76% 的健康增長率增長。

胃食管反流病 (GERD) 是一種慢性疾病，胃酸和其他內容物反流回食道，導致胃灼熱、反流和吞嚥困難等症狀。 稱為下食管括約肌 (LES) 的一圈肌肉通常會阻止胃內容物回流到食道。我會逃跑。 GERD 可能由多種因素引起，包括肥胖、懷孕、某些藥物和食管裂孔疝（胃的一部分被向上推過橫膈膜進入胸部的情況）。 GERD 的治療通常包括改變生活方式（例如避免不良食物、減肥和戒菸）和減少胃酸量的藥物。 嚴重的病例可能需要手術來加強 LES 或修復裂孔疝。 GERD 藥物的目標是減少胃酸量並減輕症狀的嚴重程度。 市場需求主要受人口老齡化、患者和醫療保健提供者對 GERD 及其相關症狀的認識提高、早期診斷和治療的推動，這反過來又推動了對 GERD 療法的需求。它是由以下因素引起的：

此外，GERD 的患病率在世界範圍內呈上升趨勢，這主要是由於飲食習慣的改變、肥胖率上升和人口老齡化所致。 因此，尋求治療的患者數量不斷增加，推動了對 GERD 療法的需求。 根據美國國家醫學圖書館的數據，2019 年全球有 7.8395 億 GERD 患者，因此這些因素預計將進一步增加全球市場對 GERD 療法的需求。 此外，GERD 治療的重大技術進步，如微創手術和內窺鏡治療，正在推動對這些治療的需求。需求正在增加。 這為公司提供了在 GERD 治療市場擴大其 OTC 藥物的機會，這將在未來幾年提供市場增長機會。 然而，不良的藥物管道和患者死亡率限制了 2022-2029 年預測期內的市場增長。

全球胃食管反流藥物市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於人口增長導致 GERD 治療的使用增加，北美在銷售方面佔據市場主導地位。 另一方面，預計亞太地區將在預測期內以最高增長率增長。 GERD 患病率上升、目標市場治療知識增加以及主要市場進入者產品線多樣化等因素正在推動預測期內的市場增長。

本研究的目的是闡明近年來各個細分市場和國家/地區的市場規模，並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含供利益相關者投資的潛在微觀市場機會，以及對主要參與者的競爭格局和產品供應的深入分析。 .

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • 2019-2029 年按地區劃分的胃食管反流藥物市場
    • 2019-2029 年按藥物類型劃分的胃食管反流藥物市場
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章胃食管反流藥物全球市場的定義和範圍

  • 調查目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 本次調查涵蓋的年份
  • 貨幣兌換率

第三章全球胃食管反流藥物市場動態

  • 胃食管反流藥物市場影響分析 (2019-2029)
    • 市場驅動力
      • 老年人口增加
      • 提高對 GERD 藥物的認識
      • GERD 的患病率越來越高
    • 市場挑戰
      • 藥物管線不佳，患者死亡率高
    • 市場機會
      • GERD 治療方案的技術進步
      • 對非處方 (OTC) GERD 治療的需求不斷增長

第四章全球胃食管反流藥物市場分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 主要投資機會
  • 關鍵成功策略
  • 業內人士的前景
  • 分析師的建議和結論

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球胃食管反流藥物市場：按藥物類型分類

  • 市場概況
  • 全球胃食管反流藥物市場：按藥物類型、性能-潛力分析
  • 2019-2029 年按藥物類型劃分的胃食管反流藥物市場估計和預測
  • 胃食管反流藥物市場細分分析
    • 抗酸劑
    • H2 受體阻滯劑
    • 質子泵抑製劑 (PPI)
    • 促動力劑

第 7 章全球胃食管反流藥物市場：區域分析

  • 胃食管反流藥物市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 2019-2029 年按藥物類型估算和預測
    • 加拿大
  • 歐洲胃食管反流藥物市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲
  • 亞太地區胃食管反流藥物市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲胃食管反流藥物市場概況
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 世界其他地區

第 8 章衝突信息

  • 主要市場策略
  • 公司簡介
    • 葛蘭素史克公司
      • 關鍵信息
      • 概覽
      • 財務（僅當數據可用時）
      • 產品概覽
      • 近期趨勢
    • Pfizer, Inc.
    • Sanofi S.A.
    • Johnson & Johnson Pvt. Ltd.
    • Glenmark Pharmaceuticals Ltd
    • Camber Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited.
    • Ironwood Pharmaceuticals, Inc.
    • Phathom Pharmaceuticals, Inc.
    • Adcock Ingram

第9章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查的特點
  • 調查先決條件

Global Gastroesophageal Reflux Disease Therapeutics Market is valued at approximately USD 5.18 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 1.76% over the forecast period 2022-2029. Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach acid and other contents flow back up into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. Normally, a muscular ring called the lower esophageal sphincter (LES) prevents stomach contents from flowing back into the esophagus, but in GERD, this ring is weakened or relaxed, allowing stomach acid and other contents to escape into the esophagus. GERD can be caused by a variety of factors, including obesity, pregnancy, certain medications, and a hiatal hernia (a condition in which part of the stomach pushes up into the chest through the diaphragm). Treatment for GERD typically involves lifestyle modifications (such as avoiding trigger foods, losing weight, and quitting smoking) and medications to reduce the amount of acid in the stomach. In severe cases, surgery may be necessary to strengthen the LES or repair a hiatal hernia. The goal of GERD therapeutics is to reduce the amount of acid in the stomach and decrease the severity of symptoms. The market demand is primarily driven by the factors such as the increasing geriatric population, coupled with increasing awareness of GERD and its associated symptoms among patients and healthcare providers, which is leading to earlier diagnosis and treatment which in turn is driving the demand for GERD therapeutics.

In addition, the increasing prevalence of GERD is increasing worldwide, primarily due to changing dietary habits, increasing obesity rates, and an aging population. This has resulted in a growing patient population seeking treatment, which is driving the demand for GERD therapeutics. The National Library of Medicine reported that globally, there were 783.95 million GERD cases in 2019, thus, in turn, these factors are expected to escalate the demand for GERD Therapeutics in the global market. Furthermore, there have been significant technological advancements in GERD treatment options, such as minimally invasive surgery and endoscopic treatments, which are driving the demand for these treatments, as well as there is increasing demand for OTC GERD medications due to their easy availability and affordability. This presents an opportunity for companies to expand their OTC offerings in the GERD therapeutics market presenting lucrative opportunities for market growth over the forthcoming years. However, poor medication pipeline and patient mortality are restricting the market growth over the forecast period of 2022-2029.

The key regions considered for the Global Gastroesophageal Reflux Disease Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing use of GERD therapeutics as a result of the disease's rising incidence in the local population. Whereas, Asia Pacific is also expected to grow at the highest growth rate over the forecasting period. Factors such as rising incidences of the ailment, rising knowledge of its treatment among the target market, and rising emphasis on the part of major market participants to diversify their product lines are burgeoning the market growth in the forecasting years.

Major market players included in this report are:

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Sanofi S.A.
  • Johnson & Johnson Pvt. Ltd.
  • Glenmark Pharmaceuticals Ltd
  • Camber Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Ironwood Pharmaceuticals, Inc.
  • Phathom Pharmaceuticals, Inc.
  • Adcock Ingram

Recent Developments in the Market:

  • In July 2022, Adcock Ingram introduced dexlansoprazole modified release, a novel proton pump inhibitor. Professor Ronnie Fass of Ohio's Case Western Reserve University delivered the event's keynote address (United States). Prof. Fass is a recognised authority in gastroesophageal reflux disease and its diagnosis and treatment (GERD).
  • In June 2022, Glenmark Pharmaceuticals Ltd acquired the authorized generic versions of some over-the-counter medications from Wockhardt Ltd in the United States. The company's wholly-owned subsidiary Glenmark Pharmaceuticals Inc. in the USA has acquired the approved abbreviated new drug applications (ANDAs) for famotidine tablets (10 mg and 20 mg) used to treat and prevent ulcers in the stomach and intestine, as well as Lansoprazole delayed-release capsules USP, 15 mg, a medication used to treat indigestion, heartburn, and acid reflux.
  • In March 2022, Phantom Pharmaceuticals' FDA-approved medication Vonoprazan, which was created for the treatment of GERD, is now offered over the counter in Japan and other Asian nations. Also, due to the rising demand for GERD therapies in the region, a number of firms have increased their presence in Asia.

Global Gastroesophageal Reflux Disease Therapeutics Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Type, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Type:

  • Antacids
  • H2 Receptor Blockers
  • Proton Pump Inhibitors (PPIs)
  • Pro-kinetic agents

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • ROLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Gastroesophageal Reflux Disease Therapeutics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Gastroesophageal Reflux Disease Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics

  • 3.1. Gastroesophageal Reflux Disease Therapeutics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing geriatric population.
      • 3.1.1.2. Rising awareness towards GERD Therapeutics.
      • 3.1.1.3. Increasing prevalence of GERD.
    • 3.1.2. Market Challenges
      • 3.1.2.1. Poor medication pipeline and patient mortality.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Technological advancements in GERD treatment options.
      • 3.1.3.2. Increasing demand for over-the-counter (OTC) GERD medications

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Gastroesophageal Reflux Disease Therapeutics Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Gastroesophageal Reflux Disease Therapeutics Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Gastroesophageal Reflux Disease Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Antacids
    • 6.4.2. H2 Receptor Blockers
    • 6.4.3. Proton Pump Inhibitors (PPIs)
    • 6.4.4. Pro-kinetic agents

Chapter 7. Global Gastroesophageal Reflux Disease Therapeutics Market, Regional Analysis

  • 7.1. Gastroesophageal Reflux Disease Therapeutics Market, Regional Market Snapshot
  • 7.2. North America Gastroesophageal Reflux Disease Therapeutics Market
    • 7.2.1. U.S. Gastroesophageal Reflux Disease Therapeutics Market
      • 7.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
    • 7.2.2. Canada Gastroesophageal Reflux Disease Therapeutics Market
  • 7.3. Europe Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.3.1. U.K. Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.2. Germany Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.3. France Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.4. Spain Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.5. Italy Gastroesophageal Reflux Disease Therapeutics Market
    • 7.3.6. Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
  • 7.4. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.4.1. China Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.2. India Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.3. Japan Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.4. Australia Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.5. South Korea Gastroesophageal Reflux Disease Therapeutics Market
    • 7.4.6. Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
  • 7.5. Latin America Gastroesophageal Reflux Disease Therapeutics Market Snapshot
    • 7.5.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market
    • 7.5.2. Mexico Gastroesophageal Reflux Disease Therapeutics Market
    • 7.5.3. Rest of Latin America Gastroesophageal Reflux Disease Therapeutics Market
  • 7.6. Rest of The World Gastroesophageal Reflux Disease Therapeutics Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. GlaxoSmithKline plc
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Pfizer, Inc.
    • 8.2.3. Sanofi S.A.
    • 8.2.4. Johnson & Johnson Pvt. Ltd.
    • 8.2.5. Glenmark Pharmaceuticals Ltd
    • 8.2.6. Camber Pharmaceuticals, Inc.
    • 8.2.7. Takeda Pharmaceutical Company Limited.
    • 8.2.8. Ironwood Pharmaceuticals, Inc.
    • 8.2.9. Phathom Pharmaceuticals, Inc.
    • 8.2.10. Adcock Ingram

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Gastroesophageal Reflux Disease Therapeutics Market, report scope
  • TABLE 2. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 5. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 16. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
  • TABLE 69. List of primary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Gastroesophageal Reflux Disease Therapeutics Market, research methodology
  • FIG 2. Global Gastroesophageal Reflux Disease Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Gastroesophageal Reflux Disease Therapeutics Market, key trends 2021
  • FIG 5. Global Gastroesophageal Reflux Disease Therapeutics Market, growth prospects 2022-2029
  • FIG 6. Global Gastroesophageal Reflux Disease Therapeutics Market, porters 5 force model
  • FIG 7. Global Gastroesophageal Reflux Disease Therapeutics Market, pest analysis
  • FIG 8. Global Gastroesophageal Reflux Disease Therapeutics Market, value chain analysis
  • FIG 9. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Gastroesophageal Reflux Disease Therapeutics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Gastroesophageal Reflux Disease Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable